Amicus Therapeutics, Inc. (FOLD) News
Filter FOLD News Items
FOLD News Results
|Loading, please wait...|
FOLD News Highlights
- FOLD's 30 day story count now stands at 6.
- Over the past 22 days, the trend for FOLD's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- DRUG are the most mentioned tickers in articles about FOLD.
Latest FOLD News From Around the Web
Below are the latest news stories about AMICUS THERAPEUTICS INC that investors may wish to consider to help them evaluate FOLD as an investment opportunity.
Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.
Amicus Therapeutics said on Thursday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a muscle disorder called Pompe disease. The health regulator last October extended its review for a second time following delays in inspections caused by pandemic-related travel restrictions. The therapy is indicated for use in adults living with late-onset Pompe disease and those without an improvement on their current enzyme replacement therapy, the company said.
Pombiliti + Opfolda Logo Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Therapeutics to Host Conference Call Today at 12:00 p.m. ET PHILADELPHIA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has approved Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (migl
Amicus Therapeutics just cleared that benchmark with an upgrade from 77 to 82. Amicus Therapeutics is trying to complete a consolidation with a 14.10 buy point. Amicus Therapeutics earns the No. 39 rank among its peers in the Medical-Biomed/Biotech industry group.
Amicus Therapeutics, Genius Sports and Viad are part of the Zacks Screen of the Week article.
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on Monday, September 11, 2023, at 11:20 a.m. E.T.Cantor Global Healthcare Conference 2023 in New York, NY on Wednesday, September 27, 2023, at 1:15 p.m. E.T. A live audio webcast of each presentation can also be acces
PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023, being held August 29 – September 1, 2023 in Jerusalem, Israel. Oral Presentation: Pompe Disease: Abstract Title: Switching treatment from alglucosidase alfa to cipaglucosidase alfa plus miglustat positively affects m
Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for Health and Care Excellence (NICE) Issues Final Positive Recommendation PHILADELPHIA and MARLOW, United Kingdom, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Medicines and